Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Autologous immunoglobulin follicular lymphoma idiotype vaccine - Biovest/NCI; B-cell lymphoma vaccine - Biovest; BiovaxID; FNHLId1; Lympreva

Latest Information Update: 12 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Biovest International; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Follicular lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 12 Jul 2017 Discontinued - Phase-II for Mantle cell lymphoma in USA (SC)
  • 12 Jul 2017 Discontinued - Phase-III for Follicular lymphoma (Late-stage disease) in Russia and Ukraine (SC)
  • 12 Jul 2017 Discontinued - Phase-III for Follicular lymphoma (Late-stage disease) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top